Xuanzhu Biopharmaceutical Completes H-Share Full Circulation, Converts 357.25 Million Unlisted Shares

Bulletin Express05-12

Xuanzhu Biopharmaceutical Co., Ltd. announced on 12 May 2026 that it has finalised its H-share full-circulation programme, converting 357.25 million unlisted domestic shares into H shares. The newly converted shares will commence trading on the Hong Kong Stock Exchange at 9:00 a.m. on 13 May 2026.

Prior to the conversion, unlisted shares represented 68.97% of Xuanzhu Biopharmaceutical’s issued share capital, while H shares accounted for 31.03%. Following the transaction, the company’s entire issued share capital of 517.95 million shares is now composed solely of H shares, fully aligning the share structure with Hong Kong’s public market.

Management cautions shareholders and potential investors to exercise due care when dealing in the company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1112216216?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-12 17:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112216216","market":"hk","top_or_hot":-1,"title":"Xuanzhu Biopharmaceutical Completes H-Share Full Circulation, Converts 357.25 Million Unlisted Shares","media":"Bulletin Express","content":"<p>Xuanzhu Biopharmaceutical Co., Ltd. announced on 12 May 2026 that it has finalised its H-share full-circulation programme, converting 357.25 million unlisted domestic shares into H shares. The newly converted shares will commence trading on the Hong Kong Stock Exchange at 9:00 a.m. on 13 May 2026.</p>\n<p>Prior to the conversion, unlisted shares represented 68.97% of Xuanzhu Biopharmaceutical’s issued share capital, while H shares accounted for 31.03%. Following the transaction, the company’s entire issued share capital of 517.95 million shares is now composed solely of H shares, fully aligning the share structure with Hong Kong’s public market.</p>\n<p>Management cautions shareholders and potential investors to exercise due care when dealing in the company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xuanzhu Biopharmaceutical Completes H-Share Full Circulation, Converts 357.25 Million Unlisted Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXuanzhu Biopharmaceutical Completes H-Share Full Circulation, Converts 357.25 Million Unlisted Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-12 17:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Xuanzhu Biopharmaceutical Co., Ltd. announced on 12 May 2026 that it has finalised its H-share full-circulation programme, converting 357.25 million unlisted domestic shares into H shares. The newly converted shares will commence trading on the Hong Kong Stock Exchange at 9:00 a.m. on 13 May 2026.</p>\n<p>Prior to the conversion, unlisted shares represented 68.97% of Xuanzhu Biopharmaceutical’s issued share capital, while H shares accounted for 31.03%. Following the transaction, the company’s entire issued share capital of 517.95 million shares is now composed solely of H shares, fully aligning the share structure with Hong Kong’s public market.</p>\n<p>Management cautions shareholders and potential investors to exercise due care when dealing in the company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02575","symbol_name":"轩竹生物-B","start_time":0,"source_url":"","article_id":"1112216216","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112216216","pubTimestamp":1778576591,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Xuanzhu Biopharmaceutical Co., Ltd. announced on 12 May 2026 that it has finalised its H-share full-circulation programme, converting 357.25 million unlisted domestic shares into H shares. The newly...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02575":"轩竹生物-B"},"translate_title":"轩竹生物制药完成H股全流通转股3.5725万股非上市股份","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02575":1},"content_text":"Xuanzhu Biopharmaceutical Co., Ltd. announced on 12 May 2026 that it has finalised its H-share full-circulation programme, converting 357.25 million unlisted domestic shares into H shares. The newly converted shares will commence trading on the Hong Kong Stock Exchange at 9:00 a.m. on 13 May 2026.\nPrior to the conversion, unlisted shares represented 68.97% of Xuanzhu Biopharmaceutical’s issued share capital, while H shares accounted for 31.03%. Following the transaction, the company’s entire issued share capital of 517.95 million shares is now composed solely of H shares, fully aligning the share structure with Hong Kong’s public market.\nManagement cautions shareholders and potential investors to exercise due care when dealing in the company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1112216216","isCrawlerRequest":true}